Paper20179192
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
Jin D and 8 others. Cancer Res, 2010. Cited by 365 papers, by iCite.
Cite this record
ConductScience Library. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Papers, record 20179192. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20179192
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| 5'-Nucleotidase | Major topic |
| Ovarian Neoplasms | Major topic |
| T-Lymphocytes | Major topic |
| Adenosine | |
| Adenosine A2 Receptor Antagonists | |
| Animals | |
| Apoptosis | |
| Female | |
| Flow Cytometry | |
| Immunotherapy, Adoptive | |
| Mice | |
| Mice, Inbred C57BL | |
| Mice, Knockout | |
| Pyrimidines | |
| RNA, Small Interfering | |
| Receptor, Adenosine A2A | |
| Triazoles |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AI018220 | NIAID NIH HHS | United States | R01AI018220 | PubMed and NIH | NIH RePORTER |
| R01 CA149669 | NCI NIH HHS | United States | R01CA149669 | PubMed and NIH | NIH RePORTER |
| UL1 RR025767 | NCRR NIH HHS | United States | UL1RR025767 | PubMed and NIH | NIH RePORTER |
| UL1 TR000149 | NCATS NIH HHS | United States | UL1TR000149 | PubMed and NIH | NIH RePORTER |
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9553767 | Ecto-enzyme and signaling functions of lymphocyte CD73. | Immunol Rev | 1998 | https://conductscience.org/library/papers/9553767 | PubMed |
| 2 | 14550503 | A glance at adenosine receptors: novel target for antitumor therapy. | Pharmacol Ther | 2003 | https://conductscience.org/library/papers/14550503 | PubMed |
| 3 | 15776005 | Immunosuppressive networks in the tumour environment and their therapeutic relevance. | Nat Rev Cancer | 2005 | https://conductscience.org/library/papers/15776005 | PubMed |
| 4 | 18404426 | From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy. | Purinergic Signal | 2007 | https://conductscience.org/library/papers/18404426 | PubMed |
| 5 | 16718268 | Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. | Melanoma Res | 2006 | https://conductscience.org/library/papers/16718268 | PubMed |
| 6 | 9325320 | Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. | J Biol Chem | 1997 | https://conductscience.org/library/papers/9325320 | PubMed |
| 7 | 1690738 | Adenosine receptor-mediated accumulation of cyclic AMP-induced T-lymphocyte death through internucleosomal DNA cleavage. | J Biol Chem | 1990 | https://conductscience.org/library/papers/1690738 | PubMed |
| 8 | 18311159 | Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. | Br J Pharmacol | 2008 | https://conductscience.org/library/papers/18311159 | PubMed |
| 9 | 18404475 | Physiological roles for ecto-5'-nucleotidase (CD73). | Purinergic Signal | 2006 | https://conductscience.org/library/papers/18404475 | PubMed |
| 10 | 9169488 | Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. | J Clin Invest | 1997 | https://conductscience.org/library/papers/9169488 | PubMed |
| 11 | 9113412 | T cell signalling through CD73. | Cell Signal | 1997 | https://conductscience.org/library/papers/9113412 | PubMed |
| 12 | 18591671 | CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18591671 | PubMed |
| 13 | 9808167 | CD73 expression and fyn-dependent signaling on murine lymphocytes. | Eur J Immunol | 1998 | https://conductscience.org/library/papers/9808167 | PubMed |
| 14 | 18292929 | Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). | Int J Oncol | 2008 | https://conductscience.org/library/papers/18292929 | PubMed |
| 15 | 16920910 | Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. | J Immunol | 2006 | https://conductscience.org/library/papers/16920910 | PubMed |
| 16 | 18404431 | CD39 and control of cellular immune responses. | Purinergic Signal | 2007 | https://conductscience.org/library/papers/18404431 | PubMed |
| 17 | 7595232 | CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. | J Exp Med | 1995 | https://conductscience.org/library/papers/7595232 | PubMed |
| 18 | 17449799 | Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. | Blood | 2007 | https://conductscience.org/library/papers/17449799 | PubMed |
| 19 | 11171087 | Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. | Biochem J | 2001 | https://conductscience.org/library/papers/11171087 | PubMed |
| 20 | 315423 | Ecto-5'-nucleotidase activity in T and B lymphocytes from normal subjects and patients with congenital X-linked agammaglobulinemia. | J Immunol | 1979 | https://conductscience.org/library/papers/315423 | PubMed |
Cited by247
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 365 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42763389 | Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42763389 | PubMed |
| 42611560 | CD73 inhibition overcomes adaptive immune resistance to PARP inhibition in models of prostate cancer. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42611560 | PubMed |
| 42577400 | CD73 is associated with glycolysis related metabolic programs and CD8+ T cell suppression in pancreatic ductal adenocarcinoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42577400 | PubMed |
| 42094596 | Small molecules targeting the PD-1/PD-L1 axis for cancer immunotherapy. | Theranostics | 2026 | https://conductscience.org/library/papers/42094596 | PubMed |
| 42064235 | Purinergic signaling modulates endothelial-to-mesenchymal transition in human aortic valve endothelial cells. | BBA Adv | 2026 | https://conductscience.org/library/papers/42064235 | PubMed |
| 41909123 | Targeting ubiquitin-specific peptidase 22 in solid tumours: from ubiquitination to immunotherapy. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/41909123 | PubMed |
| 41631877 | A Targetable Developmental Program Coregulates Angiogenesis and Immune Evasion in Melanoma. | Cancer Discov | 2026 | https://conductscience.org/library/papers/41631877 | PubMed |
| 41613810 | PIK3R1 as a Gastric Cancer Biomarker Linked to CD73 + Treg-Mediated Immunosuppression. | Oncol Res | 2026 | https://conductscience.org/library/papers/41613810 | PubMed |
| 41573544 | Enzymatic and microenvironmental regulation in adenosine metabolism-mediated immunosuppression. | Front Immunol | 2025 | https://conductscience.org/library/papers/41573544 | PubMed |
| 41276526 | Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors. | Nat Commun | 2025 | https://conductscience.org/library/papers/41276526 | PubMed |
| 41022728 | HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques. | Nat Commun | 2025 | https://conductscience.org/library/papers/41022728 | PubMed |
| 40916400 | Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy. | Korean J Clin Oncol | 2025 | https://conductscience.org/library/papers/40916400 | PubMed |
| 40715608 | Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells. | Med Oncol | 2025 | https://conductscience.org/library/papers/40715608 | PubMed |
| 40610421 | Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. | Nat Commun | 2025 | https://conductscience.org/library/papers/40610421 | PubMed |
| 40534663 | Insights from Clinical Trials on A2A Adenosine Receptor Antagonists for Cancer Treatment. | ACS Pharmacol Transl Sci | 2025 | https://conductscience.org/library/papers/40534663 | PubMed |
| 40530308 | Therapeutic potential of adenosine receptor modulators in cancer treatment. | RSC Adv | 2025 | https://conductscience.org/library/papers/40530308 | PubMed |
| 40429961 | A Comprehensive Review of Long Non-Coding RNAs in the Cancer-Immunity Cycle: Mechanisms and Therapeutic Implications. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40429961 | PubMed |
| 40420185 | Research progress of CD73-adenosine signaling regulating hepatocellular carcinoma through tumor microenvironment. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40420185 | PubMed |
| 40390144 | The progress and prospects of targeting the adenosine pathway in cancer immunotherapy. | Biomark Res | 2025 | https://conductscience.org/library/papers/40390144 | PubMed |
| 40385579 | CD73+CD8+ T cells define a subset with anti-tumor potential in DLBCL patients. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40385579 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| ENTPD1 | 953 | PubTator's text mining | https://conductscience.org/library/genes/953 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| NT5E | 4907 | PubTator's text mining | https://conductscience.org/library/genes/4907 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20179192
GET https://conductscience.org/api/papers/v1/20179192/references?page=2